Professional Career
- 2020-Present, a member of Global Pharma Key Opinion Leader (GPKOL) for CMC/cGMP, Korea Health Industry Development Institute
- 2020-Present: ILIAS Biologics, Chief Technology Officer, Daejeon, Korea
Development of innovative exosome-based therapies that use exosomes as carriers for intracellular protein delivery.
- 2017-2019: Helixmith, SVP/Head of CMC, Seoul, Korea
Development of gene therapies for neuromuscular diseases using plasmid DNA.
- 2006-2017: US FDA/CDER/Office of Biotechnology Products, Maryland, USA
Worked as a CMC reviewer for biotech and biosimilar product reviews
Participated in cGMP manufacturing facility inspections.
- 1999-2006: US DOD, Edgewood Chemical Biological Center, Maryland, USA
Research on biologic agents and small-scale production of proteins, monoclonal antibodies, and enzymes.
- 1989-1999: Alpha-Beta Technology, Massachusetts, USA
Development of carbohydrate-based therapies for immunomodulator or wound healing, etc.
Education:
- Worcester Polytechnic Institute, Ph.D., Biochemical Engineering, Massachusetts, USA
- KAIST, MS, Chemical Engineering, Seoul, Korea
- Yonsei University, BS, Chemical Engineering, Seoul, Korea
After two masters degrees in science in France and in the USA, I started my career as a strategy consultant, working for five years in defining growth strategies for multiple medium and large companies, as well as group portfolio strategies and merger & acquisition for private equity funds. I then moved to the operations and worked for the agriculture mining industry for almost 7 years, in developing partnerships, creating market demand and growing up business in Africa, as well as integration downwards the value chain on niche markets for animal feed industry.
Having joined Syntony in 2020, I am in charge of strategy and business development for a business unit called “SubWAVE”, that extends GPS coverage underground, both for public transportation (such as rail industry and road tunnels) and for the underground mining industry.
Risto was educated as a Sea Captain, and his work history (in addition sea faring) includes:
– Maritime accident investigator
– Occupational accident investigator
– Occupational safety manager (current job).
Laura is a chemical engineer and hydrometallurgist with over 20 years’ of research experience in the minerals processing industry. Her main area of focus is in-situ recovery, or keyhole mining, which involves the injection of fluid underground, dissolution of value minerals within the orebody and fluid recovery at the surface for further processing. Laura joined the CSIRO 11 years ago from the research team of Anglo American and prior to that, worked in the research group of De Beers Consolidated Mines.
Stephen B. Harrison is the founder and managing director at sbh4 GmbH in Germany. His work focuses on decarbonisation. CCUS is a fundamental pillar of his consulting practice, and he provides advisory services in this area to several leading international operators and equipment providers. Stephen has also served as the international expert for a major Asian Development Bank project related to CCUS in Viet Nam.
With a background in industrial gases including 27 years at BOC Gases, The BOC Group and Linde Gas, Stephen has intimate knowledge of the carbon dioxide capture, purification, liquefaction, storage, transportation, and utilisation value chain from commercial, technical, and operational perspectives. For 14 years, he was a global business leader in these FTSE100 and DAX30 companies.
Stephen has extensive due diligence and investment advisory experience. PE firms, fund managers and green-tech start-ups are regular clients. As a member of the gasworld advisory board, Stephen guides this international publication, which focuses on carbon dioxide and other industrial gases.
Aernout has 25 years of drug development experience at biotechnology companies as well as CROs. This experience includes designing drug development strategies through Proof-of-Concept as well as hands-on experience in the design and conduct of early clinical studies in a breadth of therapeutic areas.
As Director, Scientific Affairs, Aernout is a member of Celerion’s respiratory and vaccine research teams and works closely with external experts in the fields of pulmonology and vaccine development to support drug development programs of Celerion’s clients.
Claus is the founder and CEO of Konsolidator. Claus has more than 20 year experience from working with financial analytics, group accounting, financial reporting, training in consolidation software, and M&A activities throughout his career.
He has previously held positions as CFO in Copenship Group A/S and Netop solutions A/S, and Financial Director in Clipper Group and A.P Moller Maersk Group.
